Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Chim Acta ; 413(19-20): 1419-23, 2012 Oct 09.
Artigo em Inglês | MEDLINE | ID: mdl-22687645

RESUMO

BACKGROUND: The detection of preclinical arterial dysfunction may improve the ability to predict the subsequent risk of its outcomes and lead to optimal strategies to prevent overt vascular damage. The aim of this study was to investigate whether high high-sensitivity C-reactive protein (hsCRP) is associated with increased arterial stiffness in Korean adults. METHODS: The association between the hsCRP and cardiac-ankle vascular index (CAVI) was evaluated in 1347 healthy adults. Multivariate logistic analyses were done to identify the association of the hsCRP levels and high CAVI (≥ 8.0). RESULTS: The age and gender adjusted mean values of the CAVI were significantly higher in the intermediate and high hsCRP groups than in the low hsCRP group. For all the study subjects, an intermediate and high hsCRP was associated with a high CAVI after adjusting for covariates. However, this association was observed only in female subjects in gender-specific analyses and did not change after further adjustment for other variables. CONCLUSIONS: Even within the normal range, a high hsCRP level was a predictor of high CAVI in healthy adult females. This finding suggests that the risk of arteriosclerosis may be high in females whose hsCRP level is > 0.1mg/dl even in low-risk females.


Assuntos
Artérias/metabolismo , Arteriosclerose/diagnóstico , Proteína C-Reativa/metabolismo , Rigidez Vascular , Adulto , Fatores Etários , Artérias/fisiopatologia , Arteriosclerose/metabolismo , Arteriosclerose/fisiopatologia , Povo Asiático , Doenças Assintomáticas , Biomarcadores/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Projetos de Pesquisa , Fatores de Risco , Fatores Sexuais
2.
Int J Radiat Oncol Biol Phys ; 66(1): 195-200, 2006 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-16839708

RESUMO

PURPOSE: To examine retrospectively whether levels of epidermal growth factor receptor (EGFR) expression can predict tumor downstaging after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. METHODS AND MATERIALS: A total of 183 patients with rectal cancer (cT3-T4 or N+) were enrolled in this study. Preoperative chemoradiotherapy consisted of 50.4 Gy of pelvic radiation with concurrent 5-fluorouracil and leucovorin bolus intravenous chemotherapy in 94 patients or oral capecitabine and leucovorin in 89 patients. EGFR expression in pretreatment paraffin-embedded tumor biopsy specimens was assessed by immunohistochemistry. EGFR expression was determined from the intensity and extent of staining. Tumor downstaging was defined as a reduction of at least one T-stage level. RESULTS: Tumor downstaging occurred in 97 patients (53%), and the tumors showed a pathologic complete response in 27 patients (15%). Positive EGFR expression was observed in 140 (76%) of 183 patients. EGFR expression levels were low in 113 patients (62%) and high in 70 patients (38%). On logistic regression analysis, the significant predictive factor for increased tumor downstaging was a low level of EGFR expression and preoperative chemotherapy using oral capecitabine (odds ratio, 0.437; p = 0.012 vs. odds ratio, 3.235; p < 0.001, respectively). CONCLUSION: A high level of EGFR expression may be a significant predictive molecular marker for decreased tumor downstaging after preoperative chemoradiotherapy in locally advanced rectal cancer.


Assuntos
Biomarcadores Tumorais/metabolismo , Receptores ErbB/metabolismo , Neoplasias Retais/metabolismo , Neoplasias Retais/patologia , Adulto , Idoso , Antimetabólitos Antineoplásicos/uso terapêutico , Capecitabina , Terapia Combinada/métodos , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapêutico , Feminino , Fluoruracila/uso terapêutico , Humanos , Leucovorina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Dosagem Radioterapêutica , Neoplasias Retais/tratamento farmacológico , Neoplasias Retais/radioterapia , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA